Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.
Recently Added/Updated trials
Clinical Core Alzheimer's Disease Core Center (ABC)
The study is at the Penn Memory Center at the University of Pennsylvania and is under the direction of David Wolk, M.D.. We are currently recruiting normal control participants ages 75 years and older. The purpose of this study is to collect, store and analyze cognitive data and biological samples, such as blood and MRI imaging, from individuals without symptoms of memory loss and/or dementia. Our goal is to improve our understanding of age-associated brain changes and our ability to diagnosis and treat brain diseases. You may be asked to participate in other imaging protocols.
MK-7684A-006: Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC
Phase 3
This trial is testing MK-7684A when given in combination with chemotherapy plus radiation therapy (concurrent chemoradiotherapy or cCRT). This trial is for people with stage 3 non-small cell lung cancer (NSCLC). Receiving cCRT is part of the standard treatment for patients with stage 3 NSCLC. MK-7684A, an experimental treatment, is an immunotherapy.
Individualized (fMRI-guided) TMS Treatment for Depression
The purpose of this study is to investigate the responses of the brain region known as the subgenual anterior cingulate cortex (sgACC) during transcranial magnetic stimulation (TMS) in individuals with depression. Specifically, investigators aim to determine whether the sgACC is engaged when TMS is delivered to specific targets and if the engagement of sgACC changes throughout a full TMS treatment intervention. To achieve this goal, the investigators will employ a combination of TMS and Magnetic Resonance Imaging (MRI) procedures.Study participation will include completing various questionnaires, clinical assessments, receiving a full transcranial magnetic stimulation (TMS) treatment intervention (every weekday for 6 weeks), and undergoing MRI scans, both with and without concurrent TMS.
HPTN 103/Purpose 4
HPTN 103/PURPOSE 4 is a study being done to see if a twice-a-year medicine that is injected can help reduce the risk of getting HIV from sharing needles for drug use.
GYROS
Gyrate atrophy (GA) is a rare inherited chorioretinal degeneration that is associated with hyperornithinemia, an inborn error of metabolism caused by autosomal recessive mutations in the ornithine aminotransferase (OAT) gene. The current standard care treatment of GA is an arginine restricted diet. To facilitate a future interventional gene therapy clinical trial, there is a need to evaluate natural history of and the relationship between potential clinical trial outcome measures.
CureTalks@Penn interviews Penn Medicine physicians about their cutting edge research and clinical trials. Our goal is to inform patients, care-givers, patient advocates and other physicians about research that occurs at Penn Medicine.
